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MaBACKGROUND The SAPIEN 3 (Edwards Lifesciences Inc., Irvine, California) transcatheter valve incorporates features
designed to address the well-known deﬁciencies of transcatheter aortic valve replacement (TAVR). An ultra–low-proﬁle
delivery system facilitates safe, controlled, and accurate implantation and an external seal minimizes paravalvular
regurgitation.
OBJECTIVES The study evaluated whether TAVR with this third-generation valve would be a viable alternative to
high- or intermediate-risk surgery for severe aortic stenosis.
METHODS The prospective study enrolled 150 patients at 16 sites in Europe and Canada. Clinical and echocardiographic
outcomes were assessed at baseline, post-procedure, and 30 days. New sizing recommendations were developed during
the course of the study.
RESULTS Patients were 83.6  5.0 years of age, with multiple comorbidities reﬂected by a Society of Thoracic Surgeons
score of 7.4  4.5% and logistic EuroSCORE of 21.6  12.3%. A transfemoral approach was chosen in 64.0% and
alternative access (transapical/direct aortic) in the remainder. At 30 days, paravalvular regurgitation was none to mild in
96.4% and moderate in 3.5%. No patient had severe regurgitation. Transfemoral implantation was associated with low
mortality (2.1%), no disabling stroke (0.0%), and fully percutaneous access and closure in 95.8%. Nontransfemoral
alternative access was associated with higher rates of mortality (11.6%) and stroke (5.6%).
CONCLUSIONS This third-generation device addresses major deﬁciencies of earlier valves in terms of ease of use,
accuracy of positioning, and paravalvular sealing. The rates of mortality and stroke with transfemoral access are among
the lowest reported and support further evaluation as an alternative to open surgery in intermediate-risk patients.
(Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve [SAPIEN3]; NCT01808287)
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2236TAVR was ﬁrst performed with a balloon-
expandable THV more than a decade ago.
This prototypic device evolved into the
SAPIEN and subsequently the SAPIEN XT
THV (Edwards Lifesciences Inc., Irvine,
California). The Edwards SAPIEN 3 (S3)
(Edwards Lifesciences Inc.) represents the
next generation of balloon-expandable THVs
(1). The S3 THV system incorporates vari-
ous new features to facilitate implantation
while mitigating against vascular injury,FIGURE 1 SAPIEN 3 Transcatheter Heart Valve andstroke, suboptimal positioning, and paravalvular
regurgitation.Delivery Systems
The Edwards SAPIEN 3 (Edwards Lifesciences Inc., Irvine, Cali-
fornia) transcatheter heart valve (center) is shown with the
transfemoral Commander (above) and transapical/direct aortic
Certitude (Edwards Lifesciences Inc.) (below) delivery systems.
SEE PAGE 2244METHODS
We prospectively evaluated the safety and efﬁcacy
of the S3 THV in 150 patients with symptomatic,
severe aortic stenosis who were enrolled at
16 sites in Europe and Canada. Patients provided
informed consent, and approvals from ethics com-
mittees were obtained. The initial 50 patients were
at high surgical risk (Society of Thoracic Surgeons
[STS] risk score $8 or logistic EuroSCORE $15).
The subsequent 100 patients were intermediate risk
or higher (STS $4 or logistic EuroSCORE $10).1 Baseline Characteristics
TF
(n ¼ 96)
96, 84.3  4.8
50/96 (52.1)
EuroSCORE 96, 19.8  10.9
RE 2 96, 5.4  3.3
e 96, 7.5  4.3
nctional class III/IV 82/96 (85.4)
ulmonary disease 25/96 (26.0)
dex VARC-2 (yes or no) 75/89 (84.3)
isease 24/95 (25.3)
al vascular disease 16/96 (16.7)
7/96 (7.3)
er 13/96 (13.5)
artery disease 57/96 (59.4)
ial infarction 11/96 (11.5)
eous coronary intervention 30/96 (31.3)
artery bypass graft 14/96 (14.6)
rillation 22/96 (22.9)
9/90 (10.0)
31/96 (32.3)
ufﬁciency 39/96 (40.6)
e/severe mitral regurgitation 10/75 (13.3)
n, mean  SD, or n/N (%).
New York Heart Association; RBBB ¼ right bundle branch block; STS ¼ Socie
RC ¼ Valve Academic Research Consortium.Standardized deﬁnitions were used in accordance
with the Valve Academic Research Consortium–2
consensus (2).
The S3 THV incorporates an optimized cobalt
chromium alloy frame (which allows for an ex-
tremely low-crimped proﬁle with high radial
strength), bovine pericardial leaﬂets, and an adaptiveTAA
(n ¼ 54)
Total
(N ¼ 150)
p Value
TF Versus TAA
54, 82.5  5.3 150, 83.6  5.0 0.0454
31/54 (57.4) 81/150 (54.0) 0.6095
54, 24.9  14.0 150, 21.6  12.3 0.0215
54, 7.7  7.9 150, 6.2  5.5 0.0483
54, 7.3  4.9 150, 7.4  4.5 0.8130
48/54 (88.9) 130/150 (86.7) 0.6242
15/54 (27.8) 40/150 (26.7) 0.8489
37/41 (90.2) 112/130 (86.2) 0.4249
14/54 (25.9) 38/149 (25.5) 1.0000
21/54 (38.9) 37/150 (24.7) 0.0032
4/54 (7.4) 11/150 (7.3) 1.0000
9/54 (16.7) 22/150 (14.7) 0.6354
39/54 (72.2) 96/150 (64.0) 0.1561
15/54 (27.8) 26/150 (17.3) 0.0142
22/54 (40.7) 52/150 (34.7) 0.2846
15/54 (27.8) 29/150 (19.3) 0.0557
19/53 (35.8) 41/149 (27.5) 0.1247
2/49 (4.1) 11/139 (7.9) 0.3279
17/54 (31.5) 48/150 (32.0) 1.0000
21/54 (38.9) 60/150 (40.0) 0.8638
16/39 (41.0) 26/114 (22.8) 0.0018
ty of Thoracic Surgeons; TAA ¼ transcatheter alternative access; TF ¼ transfemoral
TABLE 2 Procedural Characteristics
TF
(n ¼ 96)
TAA
(n ¼ 54)
Total
(N ¼ 150)
p Value
TF Versus TAA
Access N/A
Transfemoral 96/96 (100.0) N/A 96/150 (64.0)
Transapical N/A 49/54 (90.7) 49/150 (32.7)
Transaortic N/A 5/54 (9.3) 5/150 (3.3)
Femoral access site closure N/A
Surgical 4/95 (4.2) N/A 4/95 (4.2)
Percutaneous 91/95 (95.8) N/A 91/95 (95.8)
Annular diameter by TEE, mm 23.3 (18.0, 29.0) 23.0 (19.0, 28.0) 23.0 (18.0, 29.0) 0.9636
Pre-dilation BAV 94/96 (97.9) 54/54 (100.0) 148/150 (98.7) 0.5361
Procedural outcomes
Implanted valve size 0.7045
23 mm 24/96 (25.0) 16/54 (29.6) 40/150 (26.7)
26 mm 51/96 (53.1) 29/54 (53.7) 80/150 (53.3)
29 mm 21/96 (21.9) 9/54 (16.7) 30/150 (20.0)
Correct placement at intended site 95/96 (99.0) 54/54 (100.0) 149/150 (99.3) 1.0000
Post-dilation 4/96 (4.2) 1/54 (1.9) 5/150 (3.3) N/A
Second SAPIEN 3 1/96 (1.0) 0/54 (0.0) 1/150 (0.7) N/A
Type of anesthesia used <0.0001
General or conversion to general 61/96 (63.5) 54/54 (100.0) 115/150 (76.7)
Nongeneral 35/96 (36.5) 0/54 (0.0) 35/150 (23.3)
Anesthesia time, min, median, (min, max) 120.0 (0.0, 760.0) 150.0 (67.0, 245.0) 135.0 (0.0, 760.0) 0.0007
Contrast, ml 130.0 (50.0, 350.0) 97.5 (40.0, 202.0) 110.0 (40.0, 350.0) <0.0001
Fluoroscopy time, min 16.2 (6.2, 62.0) 6.8 (2.3, 41.0) 13.4 (2.3, 62.0) <0.0001
Cardiopulmonary bypass 1/96 (1.0) 0/54 (0.0) 1/150 (0.7) N/A
Conversion to open-heart surgery 1/96 (1.0) 0/54 (0.0) 1/150 (0.7) N/A
Values are n/N (%) or median (min, max).
BAV ¼ balloon aortic valvuloplasty; N/A ¼ not applicable; TEE ¼ transesophageal echocardiography; other abbreviations as in Table 1.
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2237external polyethylene terephthalate fabric seal
(Figure 1). The S3 valve is longer than previous gen-
eration balloon-expandable valves; the 23, 26, and
29 mm S3 valves have expanded heights of 18, 20, and
22.5 mm.TABLE 3 CT Parameters at Baseline
TF
(n ¼ 96)
Aortic root parameter
Annulus area,* mm2 57, 491.8  76.3
% Oversizing† 57, 7.0  11.7
Annulus diameter mean, mm 57, 24.6  2.0
% Oversizing† 57, 10.2  12.2
Aortic root calciﬁcation
Annulus calciﬁcation, moderate/severe 33/93 (35.5)
Subannular calciﬁcation, moderate/severe 26/93 (28.0)
LVOT calciﬁcation, moderate or severe 24/92 (26.1)
Access vessel parameter
Minimum diameter, mm 67, 6.6  1.2
Calciﬁcation, moderate or severe 28/69 (40.6)
Tortuosity, moderate or severe 36/69 (52.2)
Values are n, mean  SD, or n/N (%). *Values <10 mm2 were excluded from the analys
CT¼ computed tomography; LVOT¼ left ventricular outﬂow tract; MDCT¼multidetectorThe transfemoral Commander delivery catheter
provides a stable platform allowing for controlled
coaxial alignment and accurate positioning of the
THV within the native valve. The system is com-
patible with 14-F (#26 mm diameter THVs) and 16-FTAA
(n ¼ 54)
Total
(N ¼ 150)
p Value
TF Versus TAA
17, 488.0  93.0 74, 490.9  79.8 0.8800
17, 5.6  14.8 74, 6.7  12.4 0.7313
20, 24.2  2.5 77, 24.5  2.1 0.5105
20, 10.6  15.1 77, 10.3  12.9 0.9255
11/46 (23.9) 44/139 (31.7) 0.1814
10/46 (21.7) 36/139 (25.9) 0.5383
9/46 (19.6) 33/138 (23.9) 0.5259
28, 5.9  1.2 95, 6.4  1.3 0.0100
22/31 (71.0) 50/100 (50.0) 0.0089
17/30 (56.7) 53/99 (53.5) 0.8268
is. †% oversizing ¼ (THV nominal area/MDCT annular area – 1)  100.
computed tomography; THV¼ transcatheter heart valve; other abbreviations as in Table 1.
TABLE 4 Clinical Outcomes at 30 Days in the AT Population
Variable
TF
(n ¼ 96)
TAA
(n ¼ 54)
Total
(N ¼ 150)
Mortality
All-cause mortality – AT population 2/96 (2.1) 6/54 (11.1) 8/150 (5.3)
All-cause mortality – VI population
(primary endpoint)
1/95 (1.1) 6/54 (11.1) 7/149 (4.7)
Cardiac mortality 2/96 (2.1) 5/54 (9.3) 7/150 (4.7)
Stroke
All strokes 1/96 (1.0) 3/54 (5.6) 4/150 (2.7)
Disabling 0/96 (0.0) 0/54 (0.0) 0/150 (0.0)
Nondisabling 1/96 (1.0) 3/54 (5.6) 4/150 (2.7)
TIA 1/96 (1.0) 1/54 (1.9) 2/150 (1.3)
Rehospitalization 0/96 (0.0) 0/54 (0.0) 0/150 (0.0)
Vascular complication
Major 4/96 (4.2) 4/54 (7.4) 8/150 (5.3)
Acute kidney injury (stage II/III) 1/96 (1.0) 3/54 (5.6) 4/150 (2.7)
Bleeding
Life threatening 3/96 (3.1) 3/54 (5.6) 6/150 (4.0)
Major 19/96 (19.8) 11/54 (20.4) 30/150 (20.0)
Coronary obstruction 0/96 (0.0) 0/54 (0.0) 0/150 (0.0)
Myocardial infarction 2/96 (2.1) 0/54 (0.0) 2/150 (1.3)
Valve dysfunction requiring a
repeat procedure*
1/96 (1.0) 0/54 (0.0) 1/150 (0.7)
Endocarditis† 0/95 (0.0) 0/54 (0.0) 0/149 (0.0)
Valve thrombosis† 0/95 (0.0) 0/54 (0.0) 0/149 (0.0)
New onset atrial ﬁbrillation 7/96 (7.3) 11/54 (20.4) 18/150 (12.0)
New LBBB 20/96 (20.8) 7/54 (13.0) 27/150 (18.0)
New pacemaker 12/96 (12.5) 8/54 (14.8) 20/150 (13.3)
Values are n/N (%). *Malposition with a second SAPIEN 3 (Edwards Lifesciences Inc., Irvine, California)
valve-in-valve implant at follow-up. †Valve-implanted population.
AT ¼ as-treated; LBBB ¼ left bundle branch block; TIA ¼ transient ischemic attack; VI ¼ valve-implanted;
other abbreviations as in Table 1.
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FIGURE 2 Changes in Echocardiographic Transaortic Mean Gradient and EOA
Line graph shows changes in the mean aortic gradient (salmon) and effective oriﬁce area
(EOA) (blue) of patients at risk from baseline to discharge and 30 days.
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2238(29 mm THV) expandable introducer sheaths. The
transapical/direct aortic Certitude (Edwards Life-
sciences Inc.) delivery catheter has an ergonomic
design, which allows for single-operator THV im-
plantation using an 18-F (#26 mm THV) or 21-F sheath
(29 mm THV). Both delivery systems incorporate a
central balloon marker, which is the primary land-
mark for positioning during THV expansion.
ECHOCARDIOGRAPHIC AND COMPUTED TOMOGRAPHY
ANALYSIS. Transthoracic echocardiograms performed
at baseline, prior to hospital discharge, and at 30
days were read by an independent core laboratory
(Cleveland Clinic, Cleveland, Ohio) according to
standard criteria that incorporate regurgitant volume,
regurgitant fraction, and effective regurgitant oriﬁce
area (2,3).
Patients were evaluated with 3-dimensional mul-
tidetector computed tomography (CT). Measurements
were performed in accordance with Society of Car-
diovascular Computed Tomography guidelines by a
centralized core laboratory (St. Paul’s Hospital, Van-
couver, Canada) (4). Aortic valve calciﬁcation was
graded semiquantitatively: none, mild (small isolated
spots), moderate (multiple larger spots), and severe
(extensive calciﬁcation of all cusps). If present, the
distribution of calciﬁcation and extension into
the left ventricular outﬂow tract (LVOT) was also
assessed as follows: mild, 1 nodule of calcium
extending <5 mm and covering <10% of the perim-
eter of the annulus; moderate, 2 nodules or 1 extend-
ing >5 mm or covering >10% of the perimeter of the
annulus; and severe, multiple nodules or a single
focus extending >1 cm in length or covering >20% of
the perimeter of the annulus (5).
SIZING STRATEGY. The S3 THV was supplied with
labeled diameters of 23, 26, and 29 mm. When fully
expanded with an appropriately sized balloon, these
THVs had predicted diameters of 22.75, 25.71, and
28.75 mm with externals of 406, 519, and 649 mm2,
respectively.
The selection of an appropriately sized THV was at
the discretion of the individual operator, informed by
procedural transesophageal echocardiography and
annular measurements and recommendations pro-
vided by the CT core laboratory. Sizing recommen-
dations were based on annular area measurements
with the percentage of oversizing (positive percent-
age) or undersizing (negative percentage) calculated
using the formula: % oversizing ¼ (THV nominal
area/MDCT annular area – 1)  100.
Prior to this study, sizing guidelines established for
the earlier SAPIEN XT THV were utilized for the S3
THV. These recommended selecting a THV with an
100%
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FIGURE 4 Functional and Quality-of-Life Outcomes
Signiﬁcant improvements were seen at 30 days in New York Heart Association (NYHA) func-
tional class (A), Canadian Cardiovascular Society (CCS) angina class (B), quality of life (VAS
EQ-5D) (C), and 6-min walk test distance (D). EQ-5D¼ EuroQoL; VAS¼ Visual Analog Scale.
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FIGURE 3 Echocardiographic AR
The stacked column graph shows total aortic regurgitation (left) and paravalvular aortic
regurgitation (AR) (right) at baseline and 30 days.
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2239expanded area at least 5% larger than that of the
annulus (5% oversizing) (1,6). During the course of
this study, the requirement for routine oversizing was
discontinued so as to allow selection of a THV up
to 5% smaller than the CT-derived annulus area
(5% undersizing).
STATISTICAL ANALYSIS. Continuous variables were
summarized as mean  SD or as medians (minimum,
maximum) as appropriate, and were compared using
Student t test or Wilcoxon rank sum test. Categorical
variables were compared using the Fisher exact test.
Additionally, New York Heart Association functional
class and Canadian Cardiovascular Society angina
values at 30 days were compared to baseline values
using the Bowker’s test of symmetry to assess the
shifts across 4 ordinal classes. An alpha level of 0.05
was used for all hypothesis testing. No multiplicity
adjustment was performed. All statistical analyses
were performed using SAS software version 9.3 (SAS
Institute, Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS. Mean age was 83.6 
5.0 years and 54% of patients were female. As shown
in Table 1, patients had multiple comorbidities with a
predicted risk of operative mortality of 7.4  4.5% by
STS and by 21.6  12.3% by logistic EuroSCORE
estimates.
Transcatheter alternative access (transapical and
direct aortic) patients, as compared to transfemoral
patients, were a higher-risk group (Table 1). They had
signiﬁcantly more moderate to severe mitral regur-
gitation (41.0% vs. 13.3%; p ¼ 0.0018), peripheral
vascular disease (38.9% vs. 16.7%; p ¼ 0.0032), and
myocardial infarction (27.8% vs. 11.5%; p ¼ 0.0142) as
well as trends toward more coronary disease (p ¼
0.1561), atrial ﬁbrillation (p ¼ 0.1247), and bypass
surgery (p ¼ 0.0557), and a higher logistic EuroSCORE
(p ¼ 0.0215). Transcatheter alternative access patients
were more likely to undergo general anesthesia
(100.0% vs. 63.5%; p < 0.0001) and anesthesia time
was longer (153.0 min vs. 128.9 min; p ¼ 0.0007),
while they received less contrast (96.9 ml vs.
148.7 ml; p < 0.0001) and had a shorter ﬂuoroscopy
time (7.6 min vs. 17.5 min; p < 0.0001) (Table 2).
CT ﬁndings at baseline are shown in Table 3.
Moderate or severe calciﬁcation was commonly seen;
it was annular in 31.7%, subannular in 25.9%, and
in the LVOT in 23.9%. Mean annular area in mid-
systole was 490.9  79.8 mm2. Mean diameter from
CT was 24.5  2.1 mm (Table 3), as compared to
a 2-dimensional transesophageal echocardiography
diameter of 23.2  2.3 mm (Table 2). For patients
CENTRAL ILLUSTRATION 30-Day Mortality in the Transfemoral as-Treated TAVR Population
Comparison of 30-day mortality outcomes using varied transfemoral balloon-expandable aortic valve replacement (TAVR) studies. *This
outcome is for the intent-to-treat population. CE ¼ Conformité Européenne; PARTNER ¼ Placement of AoRTic traNscathetER valves trial;
SOURCE ¼ Edwards SAPIEN Aortic Bioprosthesis European Outcome Registry.
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2240undergoing transfemoral access, the minimum access
artery diameter was 6.6  1.2 mm with moderate or
severe calciﬁcation and tortuosity in 40.6% and
52.2%, respectively.
PROCEDURE. Access was transfemoral in 96 patients
(64.0%). Alternative access (transapical or direct
aortic) was utilized in 54 patients (36.0%). Implanted
valves were 23 mm in 26.7% of patients, 26 mm in
53.3%, and 29 mm in 20.0%. The catheter system was
routinely able to deliver the valve to and across the
native valve in an atraumatic manner, to achieve
accurate coaxial positioning, and to facilitate con-
trolled stable THV expansion. Malposition occurred
in 1 patient (0.7%), as did annular rupture. CT anal-
ysis suggested excessive oversizing (approximately
25% by area) and the presence of severe subannular
calciﬁcation. This patient underwent conversion to
open heart surgery. Procedural characteristics are
detailed in Table 2.
OUTCOMES AT 30 DAYS. All-cause mortality was
2.1% in the transfemoral access cohort and 11.1% in
the alternative access cohort (p ¼ 0.03). Strokes were
reported in 1% of transfemoral patients and 5.6% of
alternative access patients (p ¼ 0.13).
Pacemakers were required in 13.3% of all patients.
One patient with THV malposition underwent repeat
intervention with implantation of a second S3 THV
during follow-up. No patient suffered coronary
obstruction, device embolization, or rehospitaliza-
tion. Clinical outcomes are shown in Table 4.Transthoracic echocardiography at 30 days showed
a reduction in mean gradient from 45.2  14.5 mm Hg
to 10.6  4.7 mm Hg and an increase in valve area from
0.6  0.2 cm2 to 1.5  0.4 cm2 (Figure 2). Paravalvular
regurgitation was absent or trace in 74.3%, mild in
22.1%, and moderate in 3.5%. No patient developed
severe paravalvular regurgitation (Figure 3).
Patients in New York Heart Association functional
class $3 fell from 88.1% at baseline to 6.6% at
30 days. Similarly at follow-up, 97% of patients were
in Canadian Cardiovascular Society angina class #1.
There were signiﬁcant improvements in quality of life
as documented by both visual analogue and 6-min
walk testing (Figure 4).
DISCUSSION
The 30-day mortality rate of 2.1% for patients un-
dergoing transfemoral access is among the lowest
ever reported in a large multicenter series (Central
Illustration) (7-12). The contrasting mortality of 11.1%
in patients undergoing an alternative access proce-
dure is consistent with a higher risk cohort with
higher rates of peripheral and coronary arterial dis-
ease. Consistent with this, multisystem failure played
a role in none of the transfemoral deaths, but did in
all of the alternative access deaths. By way of clinical
comparison, in the STS/American College of Cardiol-
ogy Transcatheter Valve Therapy high-risk registry,
despite a similar STS-predicted risk proﬁle, trans-
femoral mortality rates of 5.0% were more than
TABLE 5 Sizing Guidance for the SAPIEN 3 THV on the Basis of
3-Dimensional CT Dimensions
CT Dimension
Area Oversizing,* %
THV
Area-Derived Diameter, mm Annular Area, mm2 23 mm 26 mm 29 mm
20.0 314 29.3
20.2 320 26.9
20.5 330 23.0
20.7 338 20.1
21.0 346 17.3
21.1 350 16.0
21.4 360 12.8
21.7 370 9.7
22.0 380 6.8
22.3 390 4.1
22.6 400 1.5 29.8
22.8 410 –1.0 26.6
23.0 415 –2.2 25.1
23.1 420 –3.3 23.6
23.4 430 –5.6 20.7
23.7 440 –7.7 18.0
23.9 450 –9.8 15.3
24.0 452 14.8
24.2 460 12.8
24.5 470 10.4
24.7 480 8.1
25.0 490 5.9
25.2 500 3.8 29.8
25.5 510 1.8 27.3
25.7 520 –0.2 24.8
26.0 530 –2.1 22.5
26.2 540 –3.9 20.2
26.4 546 –4.9 18.9
26.5 550 –5.6 18.0
26.7 560 –7.3 15.9
26.9 570 –8.9 13.9
27.2 580 11.9
27.4 590 10.0
27.6 600 8.2
27.9 610 6.4
28.0 615 5.5
28.1 620 4.7
28.3 630 3.0
28.5 640 1.4
28.8 650 –0.2
29.0 660 –1.7
29.2 670 –3.1
29.4 680 –4.6
29.5 683 –5.0
29.6 690 –5.9
29.9 700 –7.3
Given a known annulus area, the percentage of over or under sizing can be determined for a given
valve size. The recommended ranges for individual valves are in bold. *% annular area over (þ) or
under (–) sizing as estimated by computed tomography (CT).
THV ¼ transcatheter heart valve.
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2241double that reported here, while nontransfemoral
mortality was similar at 10.8% (13).
ACCESS. The S3 low-proﬁle transfemoral system was
associated with a low (4.2%) rate of major vascular
complications and no access-related mortality.
Notably, prior studies commonly utilized open surgi-
cal arterial access; in the current study, percutaneous
access and closure were routine (95.8% of patients).
Transfemoral patients had a minimum access arterial
diameter of only 6.6  1.2 mm despite frequent tor-
tuosity and calciﬁcation, suggesting that an increas-
ingly broad spectrum of patients will be candidates
for a fully percutaneous transfemoral procedure.
STROKE. The 30-day stroke rate of 2.7% (femoral and
nontransfemoral combined) compares favorably with
the 4.3% and 4.9% rates seen in recent PARTNER 2
(Placement of AoRTic TraNscathetER Valves Trial)
SAPIEN XT and CoreValve high-risk randomized
studies (10,14). More dramatic is the low rate of stroke
(0% disabling, 1.0% nondisabling) associated with
transfemoral access.
Transcranial Doppler studies have demonstrated
that cerebral emboli are most common as the THV
crosses, or is positioned or repositioned within, the
native valve (15). Repeated implantation attempts,
valve dislodgement, and repositioning have been
associated with an increase in stroke (16). Balloon
dilation, performed after initial THV expansion to
reduce paravalvular regurgitation, also has been
associated with an increase in embolic stroke (17-19).
A low-proﬁle delivery system that facilitates atrau-
matic implantation, potentially without pre-dilation
and with very low rates of post-dilation (3.3%)
reported here, might be expected to be associated
with a relative reduction in stroke risk.
ATRIOVENTRICULAR BLOCK. New onset left bundle
branch block was observed in 18% of patients, similar
to the 12% to 30% rate reported following TAVR with
balloon-expandable valves and lower than the 29% to
65% rate seen with current self-expanding valves
(20). New left bundle branch block has been associ-
ated with an increased need for pacemakers, reduced
left ventricular function, and poorer functional status
(20). Similarly, the rate of new pacemaker implanta-
tion was 13.3%, a rate higher than generally reported
with balloon-expandable valves, but lower than that
seen with self-expanding valves (9,11,14). Early in this
experience, operators tended to use a positioning
technique similar to the SAPIEN XT THV, although
the S3 THV is 3 to 4 mm longer than earlier balloon-
expandable THVs. As the trial progressed it was rec-
ommended that the S3 be deployed slightly more
PERSPECTIVES
COMPETENCY IN PATIENT CARE: TAVR has
become an accepted option for patients with severe,
symptomatic aortic valve stenosis at high risk of
complications associated with surgical aortic valve
replacement but technological improvements must be
demonstrated to accept a catheter-based alternative
to surgery in low- or intermediate-risk patients.
TRANSLATIONAL OUTLOOK: The low rates of
stroke, vascular complications, paravalvular regurgi-
tation, and mortality associated with transfemoral
delivery of the SAPIEN 3 (Edwards Lifesciences Inc.,
Irvine, California) aortic valve prosthesis warrant
further study of TAVR in intermediate-risk patients.
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centered at or just above, rather than below, the
annular plane. Early clinical experience suggests that
this approach may reduce the need for pacemaker
implantation.
AORTIC REGURGITATION. Paravalvular regurgita-
tion occurs commonly with TAVR and has been
associated with poorer late survival. Comparing rates
of paravalvular regurgitation between series, or
between core laboratories, is difﬁcult. However, the
3.5% rate of at least moderate paravalvular regurgi-
tation is extremely low by any estimate. At 1 month,
96.4% of patients had no, trivial, or mild leaks. None
had severe regurgitation. Importantly, the low rate
and severity of paravalvular regurgitation was real-
ized with modest area oversizing of <7%, which is
well below the required area oversizing for prior
balloon expandable prostheses.
Effective annular sealing requires accurate posi-
tioning of the THV within the native annulus. Accu-
rate positioning is facilitated by the stable THV
delivery platform; deﬂection controls that facilitate
coaxial alignment; and slow, controlled balloon
expansion. Almost all valves (99.3%) were placed at
the intended location. Importantly, the external
adaptive sealing cuff appeared to allow for effective
sealing even in areas the implant frame was not
directly apposed to the annulus.
SIZING GUIDELINES. Prior to this study, the sizing
guidelines established for the earlier SAPIEN XT THV
were utilized for the S3 THV. The guidelines recom-
mended selecting a THV with an expanded area at
least 5% larger than the annulus to achieve optimal
paravalvular sealing (1,6). This approach may have
been the result of routine underestimation of annular
dimensions by 2-dimensional echocardiography.
With only 3 THV sizes available, the implanting
physician was sometimes faced with choosing
between a smaller THV with the potential for
paravalvular leak or the next larger THV with the
potential for annular injury or rupture. In such
circumstances, underexpansion of an oversized THV
by underﬁlling the deployment balloon was some-
times employed to reduce the risk of annular rupture
(21). However, there are concerns that excessively
underexpanded THVs may suffer from reduced
leaﬂet durability.
During our early S3 experience, it became apparent
that the absence of oversizing, or even modest
undersizing, was compatible with effective sealing
when enabled by the external sealing cuff and accu-
rate positioning. However, undersizing assumes
accurate 3-dimensional CT estimates of annulardimensions (22). New CT-based area guidelines were
developed that recommended an acceptable lower
range of –5% (undersizing).
Recent data demonstrate that extreme area over-
sizing (>20%) is a predictor of annular injury (5%).
Undersizing (as much as –5%) may be preferable to
extreme oversizing to reduce this risk. Similarly
calciﬁcation involving the LVOT is also a predictor of
annular injury (5). Consequently, in this setting, an
even narrower sizing range of –5% (undersizing)
to þ10% (oversizing) may be desirable (5). Proposed
CT area-based sizing guidelines are shown in Table 5.
These guidelines will require validation in future
studies.
STUDY LIMITATIONS. This study was limited pri-
marily by the learning curve associated with the use
of a new device and by the sample size.
CONCLUSIONS
The S3 THV addresses major deﬁciencies of earlier
transcatheter valves in terms of ease of use, accuracy
of positioning, and paravalvular sealing. The low-
proﬁle delivery system permits safe and fully percu-
taneous arterial access in the majority of patients.
The low rates of mortality, stroke, vascular compli-
cations, and paravalvular regurgitation achieved with
transfemoral access are among the lowest reported to
date and support further evaluation of this new de-
vice as an alternative to surgery in intermediate risk
patients.
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